Atrial fibrillation pearls and perils of management

Western Journal of Medicine

Volumn 164, Issue 5, 1996, Pages 425-434

  Kudenchuk, Peter J ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR RESPONSE; CATHETER ABLATION; CONFERENCE PAPER; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART ELECTROPHYSIOLOGY; HIGH RISK POPULATION; HUMAN; RISK BENEFIT ANALYSIS; SINUS RHYTHM; THROMBOEMBOLISM; TREATMENT PLANNING;

ANTI-ARRHYTHMIA AGENTS; ANTICOAGULANTS; ATRIAL FIBRILLATION; HUMANS; PROGNOSIS; RECURRENCE; RISK FACTORS; SURVIVAL RATE;

EID: 0029967313     PISSN: 00930415     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (109)

1. Halperin JL, Hart RG: Atrial fibrillation and stroke: New ideas, persisting dilemmas. Stroke 1988; 19:937-941
2. Copenhagen City Heart Study. Scand J Soc Med 1989; 17(suppl):124-125
3. Carins JA, Connolly SJ: Nonrheumatic atrial fibrillation: Risk of stroke and role of antithrombotic therapy. Circulation 1991; 84:469-480
4. Godtfredsen J: Atrial fibrillation: Course and prognosis - A follow-up study of 1212 cases, In Kulbertus HE, Olsson SB, Schlepper M (Eds): Atrial Fibrillation. Mölndal, Sweden, AB Hassle, 1982, pp 134-145
5. Robles de Medina EO, Bernard R, Coumel P, Damato AN, Fisch C: WHO/ISFC Task Force: Definitions of terms related to cardiac rhythm. Am Heart J 1978; 95:796-806
6. Waldo AL: Basic mechanisms of atrial fibrillation and flutter. Cardiol Rev 1993; 1:16-23
7. Meijler FL: Atrial fibrillation: A new look at an old arrhythmia. J Am Coll Cardiol 1983; 2:391-393
8. Wijffels MCEF, Kirchhof CJHJ, Dorland R, Allessie MA: Atrial fibrillation begets atrial fibrillation: A study in awake chronically instrumented goats. Circulation 1995; 92:1954-1968
9. Petersen P, Kastrup J, Brinch K, Godtfredsen J, Boysen G: Relation between left atrial dimension and duration of atrial fibrillation. Am J Cardiol 1987; 60:382-384
10. Sgarbossa EB, Pinski SL, Maloney JD, et al: Chronic atrial fibrillation and stroke in paced patients with sick sinus syndrome - Relevance of clinical characteristics and pacing modalities. Circulation 1993; 88:1045-1053
11. Naito M, David D, Michelson EL: The hemodynamic consequences of cardiac arrhythmias - Evaluation of the relative roles of abnormal atrioventricular sequencing, irregularity of ventricular rhythm and atrial fibrillation in a canine model. Am Heart J 1983; 106:284-291
12. Khaja F, Parker JO: Hemodynamic effects of cardioversion in chronic atrial fibrillation. Arch Intern Med 1972; 129:433-440
13. Kannel WB, Abbott RD, Savage DD, McNamara PM: Epidemiologic features of chronic atrial fibrillation: The Framingham study. N Engl J Med 1982; 306:1018-1022
14. Friedman HZ, Weber-Bornstein N, Deboe SF, Mancini GB: Cardiac care unit admission criteria for suspected acute myocardial infarction in new onset atrial fibrillation. Am J Cardiol 1987; 59:866-869
15. Lauer MS, Eagle KA, Buckley JM, DeSanctis RW: Atrial fibrillation following coronary artery bypass surgery. Prog Cardiovasc Dis 1989; 31:367-378
16. Sawin CT, Geller A, Wolf PA, et al: Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med 1994; 331:1249-1252
17. Coumel P, Leclerq J: Cardiac arrhythmias and the autonomic nervous system, In Levy M, Scheinman M (Eds): Cardiac Arrhythmias - From Diagnosis to Therapy. Mt Kisco, NY, Futura, 1984, pp 37-55
18. Coumel P, Friocourt P, Mugica J, Attuel P, Leclercq JF: Long-term prevention of vagal atrial arrhythmias by atrial pacing at 90/minute: Experience with 6 cases. PACE 1983; 6(pt 1):552-560
19. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA: Independent risk factors for atrial fibrillation in a population-based cohort: The Framingham Heart Study. JAMA 1994; 271:840-844
20. Kopecky SL, Bersh BJ, McGoon MD, et al: The natural history of lone atrial fibrillation: A population-based study over three decades. N Engl J Med 1987; 317:669-674
21. Evans W, Swann P: Lone atrial fibrillation. Br Heart J 1954; 6:189-194
22. Roark SF, McCarthy EA, Lee KL, Pritchett EL: Observations on the occurrence of atrial fibrillation in paroxysmal supraventricular tachycardia. Am J Cardiol 1986; 57:571-575
23. Sung RJ, Castellanos A, Mallon SM, Bloom MG, Gelband H, Myerburg RJ: Mechanisms of spontaneous alternation between reciprocating tachycardia and atrial flutter-fibrillation in the Wolff-Parkinson-White syndrome. Circulation 1977; 56:409-416
24. Sharma AD, Klein GJ, Guiraudon GM, Milstein S: Atrial fibrillation in patients with Wolff-Parkinson-White syndrome: Incidence after surgical ablation of the accessory pathway. Circulation 1985; 72:161-169
25. Haissaguerre M, Fisher B, Labbé T, et al: Frequency of recurrent atrial fibrillation after catheter ablation of overt accessory pathways. Am J Cardiol 1992; 69:493-497
26. Meijler FL: An 'account' of digitalis and atrial fibrillation. J Am Coll Cardiol 1985; 5:60A-68A
27. Kim YI, Noble RJ, Zipes DP: Dissociation of the inotropic effect of digitalis from its effect on atrioventricular conduction. Am J Cardiol 1975; 36: 459-467
28. Gaffney RE, Kahn JB, Van Maaren EF, et al: A mechanism of the vagal effect of cardiac glycosides. J Pharmacol Exp Ther 1958; 122:423-429
29. Watanabe AM: Digitalis and the autonomic nervous system. J Am Coll Cardiol 1985; 5:35A-42A
30. Mendez R, Mendez C: The action of cardiac glycosides on the refractory period of heart tissues. J Pharmacol Exp Ther 1953: 107:24-26
31. Moe GK, Abildskov JA: Observations on the ventricular dysrhythmia associated with atrial fibrillation in the dog heart. Circ Res 1964; 14:447-460
32. Sorstein L: Role of digitalis in ventricular rate control in atrial fibrillation. In Kulbertus HE, Ollson SB, Schlepper M (Eds): Atrial Fibrillation. Molndal, Sweden, AB Hassle, 1982, pp 284-292
33. Campbell RWF, Smith RA, Gallagher JJ, et al: Atrial fibrillation in the pre-excitation syndrome. Am J Cardiol 1977; 40:514-520
34. Sellers TD Jr, Bashore TM, Gallagher JJ: Digitalis in the pre-excitation syndrome - Analysis during atrial fibrillation. Circulation 1977; 56:260-267
35. Garratt C, Antoniou A, Ward D, Camm AJ: Misuse of verapamil in pre-excited atrial fibrillation. Lancet 1989; 1:367-369
36. Morady F, DiCarlo LA Jr, Baerman JM, De Buitleir M: Effect of propranolol on ventricular rate during atrial fibrillation in the Wolff-Parkinson-White syndrome. PACE 1987; 10(pt 1):492-496
37. Falk RH: Control of the ventricular rate in atrial fibrillation, In Falk RH, Podrid PJ (Eds): Atrial Fibrillation: Mechanisms and Management. New York, NY, Raven Press, 1992, pp 255-282
38. Peters KG, Kienzle MG: Severe cardiomyopathy due to chronic rapidly conducted atrial fibrillation: Complete recovery after restoration of sinus rhythm. Am J Med 1988; 85:242-244
39. Rodriguez LM, Smeets JL, Xie B, et al: Improvement in left ventricular function by ablation of atrioventricular nodal conduction in selected patients with lone atrial fibrillation. Am J Cardiol 1993; 72:1137-1141
40. Twidale N, Sutton K, Bartlett L, et al: Effects on cardiac performance of atrioventricular node catheter ablation using radiofrequency current for drug-refractory atrial arrhythmias. PACE Pacing Clinic Electrophysiol 1993; 16: 1275-1284
41. Grogan M, Smith HC, Gersh BJ, Wood DL: Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy. Am J Cardiol 1992; 59:1570-1573
42. Roth A, Harrison E, Mitani G, Cohen JJ, Rahimtoola SH, Elkayam U: Efficacy and safety of medium- and high-dose diltiazem atone and in combination with digoxin for control of heart rate at rest and during exercise in patients with chronic atrial fibrillation. Circulation 1986; 73:316-324
43. Rawles JM: What is meant by a 'controlled' ventricular rate in atrial fibrillation? Br Heart J 1990; 63:157-161
44. Falk RH, Knowlton AA, Bernard SA, Gotlieb NE, Battinelli NJ: Digoxin for converting recent-onset atrial fibrillation to sinus rhythm: A randomized, double-blinded trial. Ann Intern Med 1987; 106:503-506
45. Rawles JM, Metcalf MF, Jennings K: Time of occurrence, duration and ventricular rate of paroxysmal atrial fibrillation: The effect of digoxin. Br Heart J 1990; 63:225-227
46. Anderson JL, Gilbert EM, Albert BG, Flecainide Supraventricular Tachycardia Study Group: Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy: A multicenter double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Circulation 1989; 89:1557-1570
47. Kowey PR, Taylor JE, Rials S, Marinchak RA: Meta-analysis of the effectiveness of prophylactic drug therapy in preventing supraventricular arrhythmia early after coronary artery bypass grafting. Am J Cardiol 1992; 69:963-965
48. Andrew TC, Reimold SC, Berlin JA, et al: Prevention of supraventricular arrhythmia after coronary artery bypass surgery: A meta-analysis of randomized control trials. Circulation 1990; 84 (suppl III):236-244
49. Jazayeri MR, Deshpande S, Dhala A, Blanck Z, Sra J, Akhtar M: Transcatheter mapping and radiofrequency ablation of cardiac arrhythmias, In O'Rourke RA (Ed): Current Problems in Cardiology, Vol 19. St Louis, Mo, Mosby, 1994, pp 285-396
50. Morady F, Calkins H, Langberg JJ, et al: A prospective randomized comparison of direct current and radiofrequency ablation of the atrioventricular junction. J Am Coll Cardiol 1993; 21:102-109
51. Huang SK, Bharati S, Graham AR, Lev M, Marcus FI, Odell RC: Closed chest catheter dissection of the atrioventricular junction using radiofrequency energy: A new method of catheter ablation. J Am Coll Cardiol 1987; 9:349-358
52. Sousa J, el-Atassi R, Rosenheck S, Calkins H, Langberg J, Morady F: Radiofrequency catheter ablation of the atrioventricular junction from the left ventricle. Circulation 1991; 84:567-571
53. Williamson BD, Man KC, Daoud E, Niebauer M, Strickberger SA, Morady F: Radiofrequency catheter modification of atrioventricular conduction to control the ventricular rate during atrial fibrillation. N Engl J Med 1994; 331:910-917
54. Cox JL, Boineau JP, Schuessler RB, et al: Electrophysiologic basis, surgical development, and clinical results of the Maze procedure for atrial flutter and atrial fibrillation. Adv Cardiac Surg 1995; 6:1-67
55. Defauw JJ, Guiraudon GM, van Hernel NM, Vermeulen FEE, Kingma JH, de Bakker JMT: Surgical therapy of paroxysmal atrial fibrillation with the 'corridor' operation. Ann Thorac Surg 1992; 53:564-571
56. Fisher CM: Embolism in atrial fibrillation. In Kulbertus HE, Olsson SB, Schlepper M (Eds): Atrial Fibrillation. Mölndal, Sweden, AB Hassle, 1982, pp 192-210
57. Sherman DG, Hart RG, Easton JD: The secondary prevention of stroke with atrial fibrillation. Arch Neurol 1986; 43:68-70
58. Starkey I, Warlow C: The secondary prevention of stroke in patients with atrial fibrillation. Arch Neurol 1986; 43:66-68
59. Siegel R, Tresch DD, Keelan MH Jr, Brooks HL: Effects of anticoagulation on recurrent systemic emboli in mitral stenosis. Am J Cardiol 1987; 60:1191-1192
60. Wolf PA, Dawber TR, Thomas HE, Kannel WB: Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: The Framingham study. Neurology 1978; 28:973-977
61. Bjerkelung CJ, Oring OM: The efficacy of anticoagulant therapy in preventing embolism related to DC electrical conversion of atrial fibrillation. Am J Cardiol 1969; 23:208-216
62. Hirsh J, Fuster V: Guide to anticoagulant therapy part 2: Oral anticoagulants. Circulation 1994; 89:1469-1480
63. Flegel KM, Hanley J: Risk factors for stroke and other embolic events in patients with nonrheumatic atrial fibrillation. Stroke 1989; 20:1000-1004
64. Onundarson PT, Thorgeirsson G, Jonmundsson E, Sigfusson N, Hardarson T: Chronic atrial fibrillation - Epidemiologic features and 14 year follow-up: A case control study. Eur Heart J 1987; 8:521-527
65. Wolf PA, Kannel WB, McGee DL, Meeks SL, Bharucha NE, McNamara PM: Duration of atrial fibrillation and imminence of stroke: The Framingham study. Stroke 1984; 14:664-667
66. Albers GW: Atrial fibrillation and stroke: Three new studies, three remaining questions. Arch Intern Med 1994; 154:1443-1448
67. Atrial Fibrillation Investigators: Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Arch Intern Med 1994; 154: 1449-1457
68. Stroke Prevention in Atrial Fibrillation Investigators: Predictors of thromboembolism in atrial fibrillation - I. Clinical features of patients at risk. Ann Intern Med 1992; 116:1-5
69. Stroke Prevention in Atrial Fibrillation Investigators: Predictors of thromboembolism in atrial fibrillation - II. Echocardiographic features of patients at risk. Ann Intern Med 1992; 116:6-12
70. Wipf JE: Anticoagulation and atrial fibrillation - Putting the results of clinical trials into practice. West J Med 1995; 163:145-152
71. Peterson P, Boysen G, Godtfredsen J, Anderson E, Andersen B: Placebocontrolled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: The Copenhagen AFASAK study. Lancet 1989; 1:175-178
72. Stroke Prevention in Atrial Fibrillation Investigators: Stroke prevention in atrial fibrillation study: Final results. Circulation 1991; 84:527-539
73. Samukawa M, Hasegawa K, Harada Y, et al: Clinical features and significance of hypertrophic cardiomyopathy with atrial fibrillation. J Cardiol 1987; 17:465-474
74. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators: The effect of low-dose warfarin on the risk of stroke in patients with non-rheumatic atrial fibrillation. N Engl J Med 1990; 323:1505-1511
75. Connolly SJ, Laupacis A, Gent M, Roberts MS, Cairns JA, Joyner C: Canadian Atrial Fibrillation Anticoagulation (CAFA) study. J Am Coll Cardiol 1991; 18:349-355
76. Ezekowitz MD, Bridgers SL, James KE, et al, for the Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators: Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med 1992; 327:1406-1412
77. European Atrial Fibrillation Trial Study Group: Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993; 342:1255-1262
78. Major ongoing stroke trials. Stroke 1994; 25:541-545
79. Stroke Prevention in Atrial Fibrillation Investigators: Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II study. Lancet 1994; 343:687-691
80. Brembilla-Perrot B, Terrier de La Chaise A. Beurrier D: [Paroxysmal atrial fibrillation: Main cause of syncope in hypertrophic cardiomyopathy.] Arch Mal Coeur Vaiss 1993; 86:1573-1578
81. Madariaga I, Carmona JR, Mateas FR, Lezaun R, de los Archos E: Supraventricular arrhythmia as the cause of sudden death in hypertrophic cardiomyopathy. Eur Heart J 1994; 15:134-137
82. Lown B: Electrical reversion of cardiac arrhythmias. Br Heart J 1967; 29:469-489
83. Diltrich HC, Erickson JS, Schneiderman T, Blacky AB, Savides T, Nicod PH: Echocardiographic and clinical predictors for outcome of elective cardioversion of atrial fibrillation. Am J Cardiol 1989; 63:193-197
84. Brodsky MA, Allen BJ, Capparelli EV, Luckett CR, Morion R, Henry WL: Factors determining maintenance of sinus rhythm after chronic atrial fibrillation with left atrial dilatation. Am J Cardiol 1989; 63:1065-1068
85. Suttorp MJ, Kingma JH, Koomen EM, van't Hof A, Tijssen JGP, Lie KI: Recurrence of paroxysmal atrial fibrillation or flutter after successful cardioversion in patients with normal left ventricular function. Am J Cardiol 1993; 71:710-713
86. Fatkin D, Kuchar DL, Thorbum CW, Feneley MP: Transesophageal echocardiography before and during direct current cardioversion of atrial fibrillation: Evidence for 'atrial stunning' as a mechanism of thromboembolic complications. J Am Coll Cardiol 1994; 23:307-316
87. Grimm RA, Steward WJ, Maloney JD, et al: Impact of electrical cardioversion for atrial fibrillation on left atrial appendage function and spontaneous echo contrast: Characterization by simultaneous transesophageal echocardiography. J Am Coll Cardiol 1993; 22:1359-1366
88. Manning WJ, Silverman DI, Katz SE, et al: Impaired left atrial mechanical function after cardioversion: Relation to the duration of alrial fibrillation. J Am Coll Cardiol 1994; 23:1535-1540
89. Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC: Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: A meta-analysis of randomized controlled trials. Circulation 1990; 82: 1106-1116
90. Szekely P, Sideris DA, Batson GA: Maintenance of sinus rhythm after atrial fibrillation. Br Heart J 1970; 32:741-746
91. Karlson BW, Torstensson I, Abjöm C, Jansson SO, Peterson LE: Disopyramide in the maintenance of sinus rhythm after electroconversion of atrial fibrillation - A placebo-controlled one-year follow-up study. Eur Heart J 1988; 9:284-290
92. Antman EM, Beamer AD, Cantillon C, McGowan N, Goldman L, Friedman PL: Long-term oral propafenone therapy for suppression of refractory symptomatic atrial fibrillation and atrial flutter. J Am Coll Cardiol 1988; 12:1005-1011
93. Jull-Moller S, Edvardsson N, Rehnqvist-Ahlberg N: Sotalol versus quinidine for maintenance of sinus rhythm after direct current conversion of atrial fibrillation. Circulation 1990; 82:1932-1934
94. Gosselink AT, Crijns HJ, Van Gelder IC, Hillige H, Wiesfeld AC, Lie KI: Low-dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or nutter. JAMA 1991; 267:3289-3293
95. Berns E, Rinkenberger RL, Jeang MK, Dougherty AH, Jenkins M, Naccarelli GV: Efficacy and safety of flecainide acetate for atrial tachycardia or fibrillation. Am J Cardiol 1987; 59:1337-1341
96. Antman EM, Beamer AD, Cautillon C, McGowan N, Friedman PL: Therapy of refractory symptomatic atrial fibrillation and atrial flutter: A staged care approach with new antiarrhythmic drugs. J Am Coll Cardiol 1990; 15: 698-707
97. Wilson JS, Podrid PJ: Side effects from amiodarone. Am Heart J 1991; 121:158-171
98. Disch DL, Greenberg ML, Holzberger PT, Malenka DJ, Birkmeyer JD: Managing chronic atrial fibrillation: A Markov decision analysis comparing warfarin, quinidine and low-dose amiodarone. Ann Intern Med 1994; 120:449-457
99. Zarembski DG, Nolan PE, Slack MK, Caruso AC: Treatment of resistant atrial fibrillation: A meta-analysis comparing amiodarone and flecainide. Arch Intern Med 1995; 155:1885-1891
100. CASCADE Investigators: Randomized antiarrhythmic drug therapy in survivors of cardiac arrest: The CASCADE study. Am J Cardiol 1993; 72: 280-287
101. Flaker GC, Blackshear JL, McBride R, Kronmal RA, Halperin JL, Hart RG: Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. J Am Coll Cardiol 1992; 20:527-532
102. Cox JL, Schuessler RB, D'Agoslino HJ, et al: The surgical treatment of atrial fibrillation: III. Development of a definitive surgical procedure. J Thorac Cardiovasc Surg 1991; 101:569-583
103. Cox JL, Boineau JP, Schuessler RB, Kater KM, Lappas DG: Five-year experience with the Maze procedure for atrial fibrillation. Ann Thorac Surg 1993; 56:814-823
104. Swartz JF, Pellersels G, Silvers J, Patten L, Cervantez D: A catheter-based curative approach to atrial fibrillation in humans. Circulation 1994; 90(suppl II):I-335
105. Haissaguerre M, Gencel L, Fisher B, et al: Successful catheter ablation of atrial fibrillation. J Cardiovasc Electrophysiol 1994; 5:1045-1052
106. Haissaguerre M, Marcus FI, Fisher B, Clementy J: Radiofrequency catheter ablation in unusual mechanisms of atrial fibrillation: Report of three cases. J Cardiovasc Electrophysiol 1994; 5:743-751
107. Mugatrod FD, Slade AKB, Sopher SM, Rowland E, Ward DE, Camm AJ: Efficacy and tolerability of transvenous low energy cardioversion of paroxysmal atrial fibrillation in humans. J Am Coll Cardiol 1995; 25:1347-1353
108. Thibault B, Talajic M, Dubuc M, Roy D: Electrical cardioversion for atrial fibrillation: How many attempts are sufficient? (Abstr) Circulation 1993; 88(suppl II):340
109. Manning WJ, Sileman DI, Keighley CS, Oettgen P, Douglas PS: Transesophageal echocardiographically facilitated early cardioversion from atrial fibrillation using short-term anticoagulation: Final results of a prospective 4.5-year study. J Am Coll Cardiol 1995; 25:1354-1361